Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres

被引：0
|
作者：
Jin-Kyoung Shim
Seonah Choi
Seon-Jin Yoon
Ran Joo Choi
Junseong Park
Eun Hee Lee
Hye Joung Cho
Suji Lee
Wan-Yee Teo
Ju Hyung Moon
Hyun Sil Kim
Eui Hyun Kim
Jae-Ho Cheong
Jong Hee Chang
Jong In Yook
Seok-Gu Kang
机构：
[1] Severance Hospital,Department of Neurosurgery, Brain Tumor Center
[2] Yonsei University College of Medicine,Precision Medicine Research Center, College of Medicine
[3] Brain Tumor Translational Research Laboratory,Department of Medical Science, BK21 Plus Project for Medical Science
[4] Severance Biomedical Research Institute,Department of Oral Pathology
[5] Yonsei University College of Medicine,Department of Surgery, BK21 Plus Project for Medical Science
[6] The Catholic University of Korea,Departments of Medical Science
[7] Yonsei University College of Medicine,undefined
[8] Cancer and Stem Cell Biology Program,undefined
[9] Duke-NUS Medical School,undefined
[10] Institute of Molecular and Cell Biology,undefined
[11] A*STAR,undefined
[12] Yonsei University College of Dentistry,undefined
[13] Yonsei University College of Medicine,undefined
[14] Yonsei University Graduate School,undefined
来源：
Cancer Cell International | / 22卷
关键词：
Etomoxir; Fatty acid oxidation; Glioblastoma; Temozolomide; Tumorsphere;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 14 条
  • [1] Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres
    Shim, Jin-Kyoung
    Choi, Seonah
    Yoon, Seon-Jin
    Choi, Ran Joo
    Park, Junseong
    Lee, Eun Hee
    Cho, Hye Joung
    Lee, Suji
    Teo, Wan-Yee
    Moon, Ju Hyung
    Kim, Hyun Sil
    Kim, Eui Hyun
    Cheong, Jae-Ho
    Chang, Jong Hee
    Yook, Jong In
    Kang, Seok-Gu
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [2] Combined treatment with 2′-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness
    Hyewon Jeong
    Junseong Park
    Jin-Kyoung Shim
    Jae Eun Lee
    Nam Hee Kim
    Hyun Sil Kim
    Jong Hee Chang
    Jong In Yook
    Seok-Gu Kang
    Journal of Neuro-Oncology, 2019, 143 : 69 - 77
  • [3] Combined treatment with 2-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness
    Jeong, Hyewon
    Park, Junseong
    Shim, Jin-Kyoung
    Lee, Jae Eun
    Kim, Nam Hee
    Kim, Hyun Sil
    Chang, Jong Hee
    Yook, Jong In
    Kang, Seok-Gu
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (01) : 69 - 77
  • [4] Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.
    McDonald, Kerrie Leanne
    Ha, Wendy
    Sevim, Hatice
    Matsuda, Kazuko
    Khasraw, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy
    Bergman, Kimberly
    Irtenkauf, Susan M.
    Hasselbach, Laura A.
    Mueller, Claudius
    Petricoin, Emanuel
    Raymon, Heather
    Mikkelsen, Tom
    Decarvalho, Ana C.
    CANCER RESEARCH, 2015, 75
  • [6] IN VITRO TUMOR TREATING FIELDS (TTFIELDS) REDUCE PROLIFERATION AND ALTER MLH1 EXPRESSION IN TEMOZOLOMIDE RESISTANT (TMZR) PATIENT-DERIVED GLIOBLASTOMA (GBM) CELLS
    Michelhaugh, Sharon
    Degen, Katherine
    Walker, Blake
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2021, 23 : 27 - 27
  • [7] Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
    La Manna, Federico
    De Menna, Marta
    Patel, Nikhil
    Karkampouna, Sofia
    De Filippo, Maria
    Klima, Irena
    Kloen, Peter
    Beimers, Lijkele
    Thalmann, George N.
    Pelger, Rob C. M.
    Jacinto, Estela
    Kruithof-de Julio, Marianna
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity (vol 10, 1012, 2020)
    La Manna, Federico
    De Menna, Marta
    Patel, Nikhil
    Karkampouna, Sofia
    De Filippo, Maria Rosaria
    Klima, Irena
    Kloen, Peter
    Beimers, Lijkele
    Thalmann, George N.
    Pelger, Rob C. M.
    Jacinto, Estela
    Kruithof-de Julio, Marianna
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
    Machida, Yukino
    Nakagawa, Makoto
    Matsunaga, Hironori
    Yamaguchi, Masayuki
    Ogawara, Yoko
    Shima, Yutaka
    Yamagata, Kazutsune
    Katsumoto, Takuo
    Hattori, Ayuna
    Itoh, Masato
    Seki, Takahiko
    Nishiya, Yumi
    Nakamura, Koichi
    Suzuki, Kanae
    Imaoka, Tomoki
    Baba, Daichi
    Suzuki, Makoto
    Sampetrean, Oltea
    Saya, Hideyuki
    Ichimura, Koichi
    Kitabayashi, Issay
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 375 - 383
  • [10] Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model
    Kawaguchi, Kei
    Igarashi, Kentaro
    Murakami, Takashi
    Chmielowski, Bartosz
    Kiyuna, Tasuku
    Zhao, Ming
    Zhang, Yong
    Singh, Arun
    Unno, Michiaki
    Nelson, Scott D.
    Russell, Tara A.
    Dry, Sarah M.
    Li, Yunfeng
    Eilber, Fritz C.
    Hoffman, Robert M.
    ONCOTARGET, 2016, 7 (52) : 85929 - 85936
12